Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study

Introduction: Sorafenib, an oral multi-kinase inhibitor, represents the standard of care for advanced hepatocellular carcinoma (HCC), even if a large number of patients have limited efficacy with respect to toxic effects. Biomarkers of efficacy or resistance have yet to be identified. In two retrospective studies, we analyzed endothelial-derived nitric oxide synthase (eNOS) and angiopoietin-2 (ANGPT2) polymorphisms and at univariate analysis,...